Sign in

CIK 0001737953

  • Non-accelerated filer
  • Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
Operating
EIN
822082553
Phone
+1 781-222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$521,860
in 2 filings

Net −$521,860. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Dhingra Kapil −$409K Director sold 50% of stake
  2. SLATTERY JOSEPH P −$113K Director sold 78% of stake

Reading 83 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-04-01 Love Colin Chief Operating Officer Grant or award +40,000 805,735
2023-04-01 Love Colin Chief Operating Officer Grant or award · Employee Stock Option (right to buy) +60,000 60,000
2023-04-01 Lewis Tanya Chief Dev. Op. Officer Grant or award +40,000 160,360
2023-04-01 Lewis Tanya Chief Dev. Op. Officer Grant or award · Employee Stock Option (right to buy) +60,000 60,000
2023-04-01 Patel Sushil Chief Strategy Officer Grant or award +40,000 170,146
2023-04-01 Patel Sushil Chief Strategy Officer Grant or award · Employee Stock Option (right to buy) +60,000 60,000
2023-04-01 Coffin Robert President & Chief R&D Officer Grant or award +45,000 1,841,197
2023-04-01 Coffin Robert President & Chief R&D Officer Grant or award · Employee Stock Option (right to buy) +67,500 67,500
2023-04-01 Astley-Sparke Philip Chief Executive Officer Grant or award +142,100 1,543,180
2023-04-01 Astley-Sparke Philip Chief Executive Officer Grant or award · Employee Stock Option (right to buy) +213,150 213,150
2022-12-09 Esposito Pamela Chief Business Officer Option exercise +15,000 $1.01 $15K 244,402
2022-12-09 Esposito Pamela Chief Business Officer Sale −15,000 $25.03 $375K 229,402
2022-12-09 Esposito Pamela Chief Business Officer Option exercise · Employee Stock Option (right to buy) −15,000 36,203
2022-12-01 Xynos Konstantinos Chief Medical Officer Grant or award +17,500 70,798
2022-12-01 Xynos Konstantinos Chief Medical Officer Grant or award · Employee Stock Option (right to buy) +26,250 26,250
2022-05-16 Love Colin Chief Operating Officer Sale −6,324 $14.59 $92K 765,735
2022-05-16 Esposito Pamela Chief Business Officer Sale −3,507 $14.59 $51K 229,402
2022-05-16 Franchi Jean M. Chief Financial Officer Sale −3,436 $14.59 $50K 95,099
2022-05-16 Lewis Tanya Chief Dev. Op Officer Sale −5,473 $14.59 $80K 120,360
2022-05-16 Patel Sushil Chief Commercial Officer Sale −10,687 $14.59 $156K 130,146

Page 9 of 19 · 365 trades